英科醫療(300677.SZ)與江蘇泗陽經濟開發區管理委員會簽訂工業項目進區合同書
格隆匯 7 月 1日丨英科醫療(300677.SZ)公佈，為滿足未來戰略發展需要，公司與江蘇泗陽經濟開發區管理委員會(“甲方”)本着平等協商、互惠互利的原則，於2020年7月1日共同簽訂了《江蘇泗陽經濟開發區工業項目進區合同書》，合同約定公司在泗陽縣投資建設江蘇英偉醫療有限公司(暫定名)，以進行非織造原料生產線及醫療用品生產製造，項目計劃固定資產總投資為10億元人民幣。
項目名稱：江蘇英偉醫療有限公司(暫定名)；主要產品：非織造原料生產線及醫療用品生產製造；投資規模：乙方固定資產總投資為10億元；畝均投資強度300萬元以上；設備投資佔總投資65%以上；註冊資本2億元人民幣或3000萬美元。實現效益：項目全面投產後，年實現畝均開票銷售300萬元以上，年畝均納税15萬元以上。
用地面積及界址：(1)原華鑫紡織南側約41.8畝土地及1棟約8287平方米廠房，東至黃河路、西至邁迪康醫療用品、南至文城路、北至項目用地紅線；(2)約99.9畝土地，東至金利醫療、西至凱達紡織、南至文城路、北至項目用地紅線；(3)原金利醫療約59.6畝土地及1棟約9075平方米廠房，東至灕江路、西至凱達紡織、南至文城路、北至項目用地紅線；3個地塊共計約201畝。用地性質及價格：工業用地，使用年限為50年；價格按現狀土地紅線面積計算，實行公開掛牌競價出讓。
因為此次新型冠狀病毒的影響，公司判斷未來醫療防護產品市場空間廣闊。此次投資合同的簽訂旨在進行非織造原料生產線及醫療用品生產製造，有利於公司的長期和持續發展，增強公司產品種類多樣化，有利於進一步提升公司業績，鞏固公司在行業內的地位，會產生良好的經濟效益和社會效益，符合公司戰略發展方向。該項目資金來源為公司自有資金或自籌資金，不會對公司的生產經營產生不利影響，不存在損害公司及全體股東利益的情形此次投資不會損害公司及股東的利益，並預計不會對公司未來的財務狀況和經營成果產生重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
